Nicox: exclusive license with Eyevance for zerviate.
(CercleFinance.com) - NicOx announces that its subsidiary Nicox Ophthalmics Inc.
has concluded an exclusive license agreement with Eyevance Pharmaceuticals LLC for the marketing of Zerviate (cetirizine ophthalmic solution) 0.24% in the United States.
Eyevance will make an initial payment of six million dollars to Nicox. In addition, Nicox could receive up to 42.5 million dollars, subject to achieving future milestones, and will receive royalties of 8% to 15%, based on future net sales.
Zerviate (previously AC-170), which was approved by the FDA on 30 May, is the first topical ocular form of the antihistamine cetirizine, approved for the treatment of ocular irritaion associated with allergic conjunctivitis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
has concluded an exclusive license agreement with Eyevance Pharmaceuticals LLC for the marketing of Zerviate (cetirizine ophthalmic solution) 0.24% in the United States.
Eyevance will make an initial payment of six million dollars to Nicox. In addition, Nicox could receive up to 42.5 million dollars, subject to achieving future milestones, and will receive royalties of 8% to 15%, based on future net sales.
Zerviate (previously AC-170), which was approved by the FDA on 30 May, is the first topical ocular form of the antihistamine cetirizine, approved for the treatment of ocular irritaion associated with allergic conjunctivitis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.